Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
28 hedge funds and large institutions have $24.4M invested in Eagle Pharmaceuticals, Inc. in 2014 Q1 according to their latest regulatory filings, with 28 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
13.65% more ownership
Funds ownership: 0% → 13.65% (+14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$5.43M |
| 2 |
DM
Deerfield Management
New York
|
+$3.86M |
| 3 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$2.84M |
| 4 |
WSA
Wall Street Associates
Lajolla,
California
|
+$2.72M |
| 5 |
JP Morgan Chase
New York
|
+$2.41M |
Top Sellers
EGRX Hedge Fund Activity: Q1 2014 in Review
28 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q1 2014, worth a combined $24.4M.
Buyers outnumbered sellers: 28 funds opened new EGRX positions and 0 closed out — a net gain of 28 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $5.43M.
- 28 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q1 2014, up from 0 in Q4 2013.
- Funds reported $24.4M of Eagle Pharmaceuticals, Inc. stock for Q1 2014.
- 28 funds opened new Eagle Pharmaceuticals, Inc. positions in Q1 2014 and 0 closed out, a net change of +28 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q1 2014 was Cormorant Asset Management, an estimated $5.43M added.
Based on aggregated 13F filings for Q1 2014.